741228-89-7

Upstream product

• 20587-30-8 5-methyl-2-nitro-benzoic acid methyl ester 
• 88071-91-4 5-bromomethyl-2-nitrobenzoic acid methyl ester 
• 161292-80-4 methyl 5-((1,3-dioxoisoindolin-2-yl)methyl)-2-nitrobenzoate 

Downstream Products

• 1253731-97-3 methyl 5-(methylsulfonamidomethyl)-2-nitrobenzoate 
• 1253731-98-4 methyl 2-amino-5-(methylsulfonamidomethyl)benzoate 
• 1253731-99-5 2-amino-5-(methylsulfonamidomethyl)benzoic acid 
• 1253732-00-1 2-amino-5-(methylsulfonamidomethyl)benzamide 
• 1253731-96-2 N-{[2-(4-hydroxy-3,5-dimethylphenyl)-4-oxo-3,4-dihydroquinazolin-6-yl]methyl}methanesulfonamide 

Relevant academic research and scientific papers

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.

NOVEL ANTI-INFLAMMATORY AGENTS

Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.